Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides.

PET novel radionuclides quantification

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
03 Oct 2021
Historique:
received: 20 07 2021
revised: 28 09 2021
accepted: 29 09 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

Scandium-44 has been proposed as a valuable radionuclide for Positron Emission Tomography (PET). Recently, scandium-43 was introduced as a more favorable option, as it does not emit high-energy γ-radiation; however, its currently employed production method results in a mixture of scandium-43 and scandium-44. The interest in new radionuclides for diagnostic nuclear medicine critically depends on the option for image-based quantification. We aimed to evaluate and compare the quantitative capabilities of scandium-43/scandium-44 in a commercial PET/CT device with respect to more conventional clinical radionuclides (fluorine-18 and gallium-68). With this purpose, we characterized and compared quantitative PET data from a mixture of scandium-43/scandium-44 (~68% scandium-43), scandium-44, fluorine-18 and gallium-68, respectively. A NEMA image-quality phantom was filled with the different radionuclides using clinical-relevant lesion-to-background activity concentration ratios; images were acquired in a Siemens Biograph Vision PET/CT. Quantitative accuracy with scandium-43/scandium-44 in the phantom's background was within 9%, which is in agreement with fluorine-18-based PET standards. Coefficient of variance (COV) was 6.32% and signal recovery in the lesions provided RC

Identifiants

pubmed: 34679525
pii: diagnostics11101826
doi: 10.3390/diagnostics11101826
pmc: PMC8535161
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Nucl Med. 2015 Jun;56(6):955-61
pubmed: 25883122
EJNMMI Radiopharm Chem. 2017;2(1):14
pubmed: 29503855
EJNMMI Phys. 2020 Mar 12;7(1):16
pubmed: 32166581
EJNMMI Phys. 2020 Jan 6;7(1):1
pubmed: 31907664
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1344-1361
pubmed: 29500480
J Nucl Med. 2019 Jul;60(7):1031-1036
pubmed: 30630944
EJNMMI Radiopharm Chem. 2020 Nov 26;5(1):28
pubmed: 33242189
EJNMMI Radiopharm Chem. 2021 May 25;6(1):19
pubmed: 34036449
Appl Radiat Isot. 2021 Apr;170:109599
pubmed: 33515928
Curr Radiopharm. 2012 Jul;5(3):187-201
pubmed: 22642388
Molecules. 2020 Feb 20;25(4):
pubmed: 32093425
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Molecules. 2020 Oct 14;25(20):
pubmed: 33066650

Auteurs

Thiago V M Lima (TVM)

Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital, 6004 Luzern, Switzerland.
Institute of Radiation Physics, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.

Silvano Gnesin (S)

Institute of Radiation Physics, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.

Klaus Strobel (K)

Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital, 6004 Luzern, Switzerland.

Maria Del Sol Pérez (MDS)

Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital, 6004 Luzern, Switzerland.

Justus E Roos (JE)

Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital, 6004 Luzern, Switzerland.

Cristina Müller (C)

Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland.

Nicholas P van der Meulen (NP)

Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland.

Classifications MeSH